Printer Friendly

VIRAL RESPONSE SYSTEMS ISSUES STATEMENT CONCERNING RISE IN SHARE PRICE

VIRAL RESPONSE SYSTEMS ISSUES STATEMENT CONCERNING RISE IN SHARE PRICE
 GREENWICH, Conn., Dec. 30 /PRNewswire/ -- Viral Response Systems Inc. (NASDAQ: VRSI) today issued a statement in connection with the recent strength and activity in its common stock which has approximately doubled in price since mid-November. Viral Response Systems markets the heated Viralizer with ViraSpray which is sold on a non-prescription basis, primarily through drug stores for the relief of the symptoms of colds, allergies, sore throat and sinusitis and retails for $35.
 Viral Response Systems, Inc. attributes the strength of its stock to the enthusiastic reception accorded to the Viralizer with ViraSpray by medical professionals when exhibited at the annual meeting of the American College of Allergy and Immunology Nov. 16-20, 1991. The Viralizer was also favorably discussed at a special session on pediatric asthma by the presenting medical doctor. Among the advantages of the Viralizer modality is an absence of side effects as demonstrated by broad consumer usage and several clinical studies.
 Since the annual meeting of the American College of Allergy and Immunology, numerous physicians have called Viral Response to obtain additional information and sample Viralizers and many have indicated that they are now recommending the Viralizer with ViraSpray for the relief of upper respiratory symptoms.
 Awareness of Viral Response Systems and the Viralizer is also benefiting from its selection in the Home Health Care plan-o-gram of the number 2 sales volume, nationwide drug store chain, which is displaying a Home Health Sign Kit depicting the Viralizer in each of its 700 plus stores.
 Additionally, in a full page advertising in the Chicago Tribune on Dec. 13, 1991, and in health page advertisements in the New York Times, the Viralizer money back pledge, reflecting actual consumer experience, has been expanded to guarantee family medical cost savings of $300 per year, in addition to Viralizer's previous pledge of the most satisfying relief of cold, allergy, sinusitis and sore throat symptoms. As the health care cost crisis is the nation's number one problem, VRS is proud to be able to make this offer.
 Viral Response Systems Inc., finished calender 1991 in a strong financial position having cash reserves in excess of $1,000,000, or about $.25 per share and virtually no debt.
 -0- 12/30/91
 /CONTACT: Robert S. Krauser, president of Viral Response Systems, 203-661-1550/
 (VRSI) CO: Viral Response Systems Inc. ST: Connecticut IN: HOU SU:


JT -- NY001 -- 2782 12/30/91 09:00 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 30, 1991
Words:407
Previous Article:AUDI QUATTRO SPYDER U.S. INTRODUCTION AT L.A. AUTO SHOW
Next Article:MEDIA CONSULTANT MICHAEL SHEEHAN CITES BEST AND WORST MEDIA PERFORMANCES OF 1991; KUDOS TO SCHWARZKOPF, THUMBS DOWN TO DUKE
Topics:


Related Articles
VIRAL RESPONSE SYSTEMS - FULL-PAGE CHICAGO TRIBUNE: 'OUR CRIME IS REDUCING MEDICAL COSTS'
VIRAL TESTING SYSTEMS CORPORATION COMPLETES SPIN-OFF OF SUBSIDIARY
TRAVIS PARTNERS EXERCISES VIRAL TESTING SYSTEMS CORPORATION WARRANTS
Pall Makes $3.0 Million Milestone Investment in VITEX; Payment Triggered with Initiation of Red Blood Cell Clinical Trials.
Aradigm Announces Gene Therapy Research Collaboration With UCSF.
Transgene Awarded European Patent Covering Non-Viral Gene Delivery Technology.
Advanced Viral Research Corp. Receives $50 Million Equity Line of Credit.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters